Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction

Activating mutations in RAS are found in approximately 30% of human cancers, resulting in the delivery of a persistent signal to critical downstream effectors that drive tumorigenesis. RAS-driven malignancies respond poorly to conventional cancer treatments and inhibitors that target RAS directly ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Durrant, David E., Smith, Emily A., Goncharova, Ekaterina I., Sharma, Nirmala, Alexander, Patrick A., Stephen, Andrew G., Henrich, Curtis J., Morrison, Deborah K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Models and Technologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419108/
https://www.ncbi.nlm.nih.gov/pubmed/34158349
http://dx.doi.org/10.1158/1535-7163.MCT-21-0175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419108/
https://www.ncbi.nlm.nih.gov/pubmed/34158349
http://dx.doi.org/10.1158/1535-7163.MCT-21-0175

Ejemplares similares